Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context

References

• BorghaeiHPaz-AresLSpigelDRNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• ArteagaCLOverview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaSemin Oncol2002295 suppl 1439
   PubMed Web of Science ®Google Scholar
• MatikasAMistiotisDGeorgouliasVKotaskisACurrent and future approaches in the management of non-small-cell lung cancer patients with resistance to EGFR TKIsClin Lung Cancer201516425226125700775
   PubMed Web of Science ®Google Scholar
• van der WekkenAJSaberAHiltermannTJKokKvan den BergAGroenHJResistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literatureCrit Rev Oncol Hematol201610010711626852079
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaAFLEX Study TeamCetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar
• HigginsJPGreenSCochrane Handbook for Systematic Reviews of Interventions: The Cochrane CollaborationChichester, UKJohn Wiley & Sons, Ltd2011
   Google Scholar
• ThatcherNHirschFRLuftAVSQUIRE InvestigatorsNecitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialLancet Oncol201516776377426045340
   PubMed Web of Science ®Google Scholar
• MiddletonMRDalleSClaveauJReal-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE studyCancer Med2016571436144327118102
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTNational Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLSATURN investigatorsErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol201011652152920493771
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• KazandjianDBlumenthalGMYuanWHeKKeeganPPazdurRFDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancerClin Cancer Res20162261307131226980062
   PubMed Web of Science ®Google Scholar
• PuzanovIDummerRSchachterJEfficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL)Poster presented at: 2015 ASCO Annual MeetingMay 29–June 2, 2015Chicago, IL Available from: http://meetinglibrary.asco.org/content/150479-156Accessed February 14, 2017
   Google Scholar
• DouillardJYOstorosGCoboMFirst-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm studyBr J Cancer20141101556224263064
   PubMed Web of Science ®Google Scholar
• InoueAKobayashiKMaemondoMUpdated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Ann Oncol2013241545922967997
   PubMed Web of Science ®Google Scholar
• GelaoLCriscitielloCEspositoAGoldhirschACuriglianoGImmune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an “innocent bystander”Toxins20146391493324594636
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• MantelNHaenszelWStatistical aspects of the analysis of data from retrospective studies of diseaseJ Natl Cancer Inst19592271974813655060
   PubMed Web of Science ®Google Scholar
• LiaoBCLinCCYangJCSecond and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancerCurr Opin Oncol20152729410125611025
   PubMed Web of Science ®Google Scholar
• YangJRamalingamSSJannePACantariniMMitsudomiTLBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) resultsJ Thorac Oncol2016114 supplS152S153
   Web of Science ®Google Scholar
• FacchinettiFTiseoMMaioMDTackling ALK in non-small cell lung cancer: the role of novel inhibitorsTransl Lung Cancer Res20165330132127413712
   PubMed Web of Science ®Google Scholar
• OuSHAhnJSDe PetrisLAlectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global studyJ Clin Oncol201634766166826598747
   PubMed Web of Science ®Google Scholar
• RothschildSNew treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinibTher Clin Risk Manag20161273574127217763
   PubMed Web of Science ®Google Scholar
• JohnsonDBEstradaMVSalgadoRMelanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyNat Commun201671058226822383
   PubMed Web of Science ®Google Scholar
• MalikSMMaherVEBijwaardKEU.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positiveClin Cancer Res20142082029203424573551
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med2013368252385239423724913
   PubMed Web of Science ®Google Scholar
• SolomonBJMokTKimDWPROFILE 1014 InvestigatorsFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
   PubMed Web of Science ®Google Scholar
• ShawATOuSHBangYJCrizotinib in ROS1-rearranged non-small-cell lung cancerN Engl J Med2014371211963197125264305
   PubMed Web of Science ®Google Scholar
• KimDWMehraRTanDSActivity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialLancet Oncol201617445246326973324
   PubMed Web of Science ®Google Scholar
• ShawATGandhiLGadgeelSStudy InvestigatorsAlectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialLancet Oncol201617223424226708155
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNon-small cell lung cancer (version 4.2017) Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfAccessed February 14, 2017
   Google Scholar
• HasaniALeighlNBTargeting vascular endothelial growth factor in lung cancerJ Thorac Oncol2010512 suppl 6S484S48621102250
   PubMed Web of Science ®Google Scholar
• GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
   PubMed Web of Science ®Google Scholar
• DrakeCGJaffeeEPardollDMMechanisms of immune evasion by tumorsAdv Immunol200690518116730261
   PubMed Web of Science ®Google Scholar
• PardollDThe blockade of immune checkpoints in cancer immunotherapyNav Rev Cancer2012124252264
   PubMed Web of Science ®Google Scholar
• La-BeckNJeanGHuynhCAlzghariSLoweDImmune checkpoint inhibitors: new insights and current place in cancer therapyPharmacotherapy2015351096397626497482
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKBaasPNivolumab versus docetaxel in advanced squamous-cell non-cell lung cancerN Engl J Med201537312313526028407
   PubMed Web of Science ®Google Scholar
• Bristol-Meyers SquibbBristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer Available from: http://investor.bms.com/investors/news-and-events/press-releases/press-release-details/2016/Bristol-Myers-Squibb-Announces-Top-Line-Results-from-CheckMate--026-a-Phase-3-Study-of-Opdivo-nivolumab-in-Treatment-Nave-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer/default.aspxAccessed February 14, 2017
   Google Scholar
• GaronEBRizviNAHuiRPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• HuiRGandhiLCostaECLong-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro)Poster presented at: 2016 ASCO Annual MeetingJune 3–7, 2016Chicago, IL, USA Available from: http://meetinglibrary.asco.org/content/167384-176Accessed August 10, 2016
   Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• ReckMRodriguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med2016375191823183327718847
   PubMed Web of Science ®Google Scholar
• FehrenbacherLSpiraABallingerMPOPLAR Study GroupAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387100301837184626970723
   PubMed Web of Science ®Google Scholar
• BarlesiFParkKCiardielloFPrimary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLCAbstract LBA44_PR presented at: European Society for Medical Oncology 2016 CongressCopenhagen, DenmarkOctober 7–11, 2016 Available at: http://www.esmo.org/Conferences/ESMO-2016-Congress/Press-Media/Significant-Survival-Gains-with-Atezolizumab-vs-Docetaxel-for-Non-Small-Cell-Lung-CancerAccessed February 14, 2017
   Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• HellmanMGettingerSGoldmanJCheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLCPaper presented at: ASCO 2016June 3–7, 2016Chicago, IL, USA
   Google Scholar
• HymanDMPuzanovISubbiahVVemurafenib in multiple nonmelanoma cancers with BRAF V600 mutationsN Engl J Med2015373872673626287849
   PubMed Web of Science ®Google Scholar
• PlanchardDKimTMMazieresJDabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trialLancet Oncol201617564265027080216
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRJrSmitEFPlanchardDA randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) daggerAnn Oncol201526589490125722381
   PubMed Web of Science ®Google Scholar
• SolimanHHJacksonENeugerTA first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumorsOncotarget20145188136814625327557
   PubMedGoogle Scholar
• PapadimitrakopoulouVLeeJJWistubaIIThe BATTLE-2 Study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancerJ Clin Oncol Epub201681
   PubMed Web of Science ®Google Scholar
• WHOLung cancer: estimated incidence, mortality and prevalence worldwide in 2012WHO2012 Available from: http://globocan.iarc.fr/old/FactSheets/cancers/lung-new.aspAccessed February 14, 2017
   Google Scholar
• TartariFSantoniMBurattiniLMazzantiPOnofriABerardiREconomic stability of anti-PD-1 agent nivolumab and pembrolizumab in cancer patients: recent insights and future challengesCancer Treat Rev201648202427310708
   PubMed Web of Science ®Google Scholar
• ChaftJNivolumab after surgery and chemotherapy in treating patients with stage IB-IIIA non-small cell lung cancer (ANVIL)2016 Available from: https://clinicaltrials.gov/ct2/show/NCT02595944 NLM identifier: NCT02595944Accessed October 25, 2016
   Google Scholar
• SquibbBMA trial of nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy, compared to platinum doublet chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC) (checkmate 227)2016 Available from: https://clinicaltrials.gov/ct2/show/NCT02595944 NLM identifier: NCT02595944Accessed October 25, 2016
   Google Scholar